France
# |
Name |
Net Cash Used Provided By Financing Activities |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 370.08 M
|
Dec. 31, 2023 | USD 5.91 | -2.66% |
|
France |
|
2 |
USD 69.63 M
|
Dec. 31, 2023 | USD 3.21 | 17.34% |
|
France |
|
3 |
USD 51.62 M
|
Dec. 31, 2023 | USD 3.47 | -1.52% |
|
France |
|
4 |
USD 32.10 M
|
Dec. 31, 2023 | USD 2.43 | 0.68% |
|
France |
|
5 |
USD 27.54 M
|
March 31, 2024 | USD 16.83 | 1.50% |
|
France |
|
6 |
USD 17.96 M
|
Dec. 31, 2023 | USD 1.64 | 4.90% |
|
France |
|
7 |
USD 14.71 M
|
Dec. 31, 2023 | USD 6.63 | -0.22% |
|
France |
|
8 |
USD 13.79 M
|
Dec. 31, 2023 | USD 1.39 | 1.77% |
|
France |
|
9 |
USD 6.77 M
|
Dec. 31, 2023 | USD 4.22 | -0.94% |
|
France |
|
10 |
USD 694.26 K
|
Dec. 31, 2023 | USD 5.64 | -2.27% |
|
France |
|
11 |
USD -1.86 M
|
Dec. 31, 2023 | USD 3.53 | -0.92% |
|
France |
|
12 |
USD -2.17 M
|
Dec. 31, 2023 | USD 2.01 | -0.78% |
|
France |
|
13 |
USD -2.17 M
|
Dec. 31, 2023 | USD 2.58 | -11.21% |
|
France |
|
14 |
USD -5.05 M
|
Dec. 31, 2023 | USD 0.65 | 1.19% |
|
France |
|
15 |
USD -17.10 M
|
Dec. 31, 2023 | USD 75.53 | 2.94% |
|
France |
|
16 |
USD -25.94 M
|
Dec. 31, 2023 | USD 26.53 | -0.92% |
|
France |
|
17 |
USD -8.89 B
|
Dec. 31, 2023 | USD 107.78 | 1.15% |
|
France |
The Vaccines company in France with the highest Net Cash Used Provided By Financing Activities is ABIVAX SA (Paris Stock Exchange: ABVX.PA) at USD 370.08 M.
The Vaccines company in France with the lowest Net Cash Used Provided By Financing Activities is Sanofi (Paris Stock Exchange: SAN.PA) at USD -8.89 B.
The top 10 Vaccines companies in France by Net Cash Used Provided By Financing Activities are ABIVAX SA, Valneva SE, Nanobiotix S.A., Inventiva S.A., MedinCell S.A., AB Science S.A., OSE Immunotherapeutics SA, Valbiotis SA, DBV Technologies S.A. and Adocia SA.
The bottom 10 Vaccines companies in France by Net Cash Used Provided By Financing Activities are Sanofi, Eurobio Scientific SA, Vetoquinol SA, Novacyt S.A., Aelis Farma SA, Innate Pharma S.A., genOway SA, Adocia SA, DBV Technologies S.A. and Valbiotis SA.